Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands.
about
Pneumococcus and the Elderly in Italy: A Summary of Available Evidence Regarding Carriage, Clinical Burden of Lower Respiratory Tract Infections and On-Field Effectiveness of PCV13 VaccinationThe whole heaven a musical scale and a number.Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project.Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study.Effects of community-wide vaccination with PCV-7 on pneumococcal nasopharyngeal carriage in the Gambia: a cluster-randomized trialSerotype replacement in disease after pneumococcal vaccinationThe status of invasive pneumococcal disease among children younger than 5 years of age in north-west Lombardy, Italy.A few years later. Update of the cost-effectiveness of infant pneumococcal vaccination in Dutch children.Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective.Serotypes and genotypes of invasive Streptococcus pneumoniae before and after PCV10 implementation in southern BrazilSalivary immune responses to the 7-valent pneumococcal conjugate vaccine in the first 2 years of life.Independent validation of an existing model enables prediction of hearing loss after childhood bacterial meningitisThe majority of adult pneumococcal invasive infections in Portugal are still potentially vaccine preventable in spite of significant declines of serotypes 1 and 5.Population genetic structure of Streptococcus pneumoniae in Kilifi, Kenya, prior to the introduction of pneumococcal conjugate vaccine.Differential B-cell memory around the 11-month booster in children vaccinated with a 10- or 13-valent pneumococcal conjugate vaccine.Direct Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants.A longitudinal study of streptococcus pneumoniae carriage in healthy children in the 13-valent pneumococcal conjugate vaccine eraPopulation Structure of Streptococcus pneumoniae Causing Invasive Disease in Adults in Portugal before PCV13 Availability for Adults: 2008-2011.Carriage of Streptococcus pneumoniae 3 years after start of vaccination program, the NetherlandsInvasive Pneumococcal Disease 3 Years after Introduction of 10-Valent Pneumococcal Conjugate Vaccine, the Netherlands.The burden of bacteremia and invasive diseases in children aged less than five years with fever in Italy.Streptococcus pneumoniae capsular serotype invasiveness correlates with the degree of factor H binding and opsonization with C3b/iC3bInvasive pneumococcal disease and 7-valent pneumococcal conjugate vaccine, the Netherlands.Cost-effectiveness of polysaccharide pneumococcal vaccination in people aged 65 and above in Poland.Active hospital-based surveillance of invasive pneumococcal disease and clinical pneumonia in infants and young children in two Polish countiesA review of the impact of pneumococcal polysaccharide conjugate vaccine (7-valent) on pneumococcal meningitisCarriage of Streptoccoccus pneumoniae in healthy adults aged 60 years or over in a population with very high and long-lasting pneumococcal conjugate vaccine coverage in children: rationale and perspectives for PCV13 implementation.Why do we need a systematic review of pneumococcal conjugate vaccine dosing schedules?Systematic review of the indirect effect of pneumococcal conjugate vaccine dosing schedules on pneumococcal disease and colonization.Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type invasive pneumococcal disease among young children.Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia.Sex differences in invasive pneumococcal disease and the impact of pneumococcal conjugate vaccination in the Netherlands, 2004 to 2015.Emerging drugs for pneumococcal pneumonia.Glycoconjugate vaccines.The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review.Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice.Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies.Pneumococcal population in the era of vaccination: changes in composition and the relation to clinical outcomes.Increasing incidence of invasive pneumococcal disease and pneumonia despite improved vaccination uptake: surveillance in Hull and East Yorkshire, UK, 2002-2009.Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: findings from cross-sectional carriage studies.
P2860
Q26739685-9BCE06A9-715E-422F-82FD-B8F08976F1EEQ33561365-6AFA7633-B5DB-45C3-95EC-016C76AA2BF4Q33722069-A743F218-413B-4DE0-8178-DB468DAD2F51Q33869370-242E5CA5-A365-41B0-9574-9AF0AA477E70Q34058016-52CA7A07-71F6-4FE4-99FB-9D14C9E643D2Q34178363-02441606-D800-4BA5-8477-E386F17FF56EQ34254800-75905A07-BD02-4984-AA1D-3B39C96EDAB1Q34291104-9AD98CBD-5B09-4F5E-9A43-9E0B16698251Q34407129-AE290C37-8665-489E-9CDB-8E64C0C2BD0DQ34428419-B83DEB10-B5C8-4C4A-A67F-67ED72117807Q34450459-A665D13D-E1F3-401A-986D-FD2790300385Q34639320-9E0846A7-C2D9-4C90-A28D-97C4AA58DAA5Q34997063-AF1AE2C8-9846-428F-AE3F-82D94D1DA492Q35055346-1CC7949E-2E35-41BD-AE09-F925A20AEB90Q35855954-B74778A6-45DA-4F6B-9CCE-832A8096A5F4Q35867061-C737215F-4086-464A-81A7-A091D69BABC5Q35887787-00E3E53B-6F8D-4F47-AFC4-29E673D4984CQ36014598-1FC515A8-C81A-48E3-88A0-895CC30EB858Q36039569-A8E5B60F-7EAB-4E91-9140-7263EFB61E48Q36211996-F8986B38-E734-4DE7-A70C-27AF1D61F7CEQ36304211-EB7D49AD-1089-4C4A-963D-66F87132580EQ36506103-C4097E52-D859-4460-9A33-C11F5BEFBC23Q36574279-41477951-1354-41D0-879B-369AE7B97C7DQ36864896-F03608AA-3E3E-4F64-818B-14DA0BC9E571Q36958318-43B4F5C0-621B-436E-B1F5-987E589F36FCQ37187296-C2170C91-8A67-474F-A5DC-830E5D9CB152Q37478339-D01B78B5-9F3C-438F-B043-4AE3C9EBF105Q37613609-92962C29-8083-4479-913C-C591D40A8B91Q37613925-CE530DE1-EBAB-4A3F-927D-A927EA7EA76BQ37621064-9BC15E17-A0F9-4D3D-AD7D-D4725A6E3C89Q37631215-DB236F60-FB83-4FE3-9746-6C86760F1955Q37708522-F1CD599E-F72A-4D54-9996-478BA6F54927Q37864327-5A10C623-7474-472A-A597-EADB6806732EQ38044755-A47013DE-EE62-464E-88CA-DA575227F082Q38080478-84FF0ED4-2563-4299-845D-8DED5B6802AFQ38082673-C047B838-728F-4558-B2B7-51089DF8F6A6Q38167294-54AAA850-FB38-40B0-A3E6-8C745A0ACCCCQ38931440-B0F7FEDB-40E2-4007-902C-45EF4487A86DQ38992874-977CFAC2-5060-4B3D-A704-BF8725E0BAF6Q39043548-407930AB-3BAC-4EB1-80A3-481EFF360089
P2860
Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Effects of pneumococcal conjug ...... introduction, the Netherlands.
@ast
Effects of pneumococcal conjug ...... introduction, the Netherlands.
@en
Effects of pneumococcal conjug ...... introduction, the Netherlands.
@nl
type
label
Effects of pneumococcal conjug ...... introduction, the Netherlands.
@ast
Effects of pneumococcal conjug ...... introduction, the Netherlands.
@en
Effects of pneumococcal conjug ...... introduction, the Netherlands.
@nl
prefLabel
Effects of pneumococcal conjug ...... introduction, the Netherlands.
@ast
Effects of pneumococcal conjug ...... introduction, the Netherlands.
@en
Effects of pneumococcal conjug ...... introduction, the Netherlands.
@nl
P2093
P2860
P356
P1476
Effects of pneumococcal conjug ...... introduction, the Netherlands.
@en
P2093
Angelique G C S Jansen
Arie van der Ende
Elisabeth A M Sanders
Gerwin D Rodenburg
Hester E de Melker
Leo M Schouls
Lodewijk Spanjaard
Sabine C de Greeff
P2860
P304
P356
10.3201/EID1605.091223
P577
2010-05-01T00:00:00Z